Prahlad Singh (MBA '00) is President and Chief Executive Officer at Revvity (formerly known as PerkinElmer), as well as a member of the Board of Directors.
With more than 25 years of leadership experience working for global healthcare companies, Prahlad is professionally and personally motivated by the opportunity to make a positive impact on the world. Under his leadership, Revvity's 11,000 employees deliver best-in-class solutions and service to a diverse range of organizations – advancing science that expands human health and improves lives worldwide.
Before his current role, Prahlad served as President and CEO of PerkinElmer, a position he was appointed to in 2019. During his time in this role, Prahlad led the company through a period of significant transformation – stewarding the organization through the COVID-19 pandemic and overseeing its dramatic portfolio evolution. He was also at the helm when the company completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, which resulted in the creation of Revvity. Prior to joining PerkinElmer in 2014, Prahlad was General Manager of GE Healthcare's Women's Health business. He has also held senior executive level roles in strategy, business development and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Born and raised in India, Prahlad holds a bachelor's degree in chemistry from the University of Bombay. He moved to the United States to continue his academic career at the University of Missouri-Columbia, where he earned a PhD in chemistry. Prahlad also holds an MBA from Northeastern University's D'Amore-McKim School of Business. Prahlad currently serves on the Board of Directors of Amphenol Corporation. Additionally, he is an honoree of the Ascend Foundation's 2023 A-List Awards recognizing outstanding Pan-Asian leaders.
Prahlad holds a Ph.D. in Chemistry from the University of Missouri-Columbia. His technical work resulted in several peer-reviewed publications and global patents. Prahlad joined CEM's board in 2018.
